We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+42.89%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$4.69B
AUM Growth
+$937M
Cap. Flow
+$184M
Cap. Flow %
3.93%
Top 10 Hldgs %
46.5%
Holding
101
New
13
Increased
10
Reduced
7
Closed
20

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$110M
2
THRD
Third Harmonic Bio
THRD
+$62.6M
3
COGT icon
Cogent Biosciences
COGT
+$55M
4
FULC icon
Fulcrum Therapeutics
FULC
+$50.1M
5
BIIB icon
Biogen
BIIB
+$44.7M

Top Sells

Rank Stock Value
1
VERU icon
Veru
VERU
+$89.3M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$61.3M
3
NTRA icon
Natera
NTRA
+$46.4M
4
DYN icon
Dyne Therapeutics
DYN
+$19.3M
5
GH icon
Guardant Health
GH
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.68%
2 Financials 0.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FUSN
76
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$1.99M 0.04%
+659,992
New +$1.65M
PYXS icon
77
Pyxis Oncology
PYXS
$198M
$1.51M 0.03%
764,653
-188,740
-20% -$493K
FTH
78
Faeth Therapeutics
FTH
$634M
$1.06M 0.02%
34,176
-2,001
-6% -$78.6K
BOLT icon
79
Bolt Biotherapeutics
BOLT
$7.59M
$789K 0.02%
26,672
+4,165
+19% +$172K
APTX
80
DELISTED
Aptinyx Inc. Common Stock
APTX
$720K 0.02%
+1,954,698
New +$979K
SYRE icon
81
Spyre Therapeutics
SYRE
$9.06B
$5K ﹤0.01%
+418
New +$5.16K
ADVM
82
DELISTED
Adverum Biotechnologies
ADVM
– –
-172,602
Closed -$2.07M
ATXS
83
DELISTED
Astria Therapeutics
ATXS
– –
-760,857
Closed -$2.28M
BCAB icon
84
BioAtla
BCAB
$5.53M
– –
-20,636
Closed -$2.94M
BMEA icon
85
Biomea Fusion
BMEA
$91.1M
– –
-500,000
Closed -$5.99M
DYN icon
86
Dyne Therapeutics
DYN
$4.89B
– –
-2,805,045
Closed -$19.3M
GH icon
87
Guardant Health
GH
$21.9B
– –
-476,380
Closed -$19.2M
IPSC icon
88
Century Therapeutics
IPSC
$353M
– –
-756,821
Closed -$6.36M
LAB icon
89
Standard BioTools
LAB
$307M
– –
-1,987,589
Closed -$3.18M
LRMR icon
90
Larimar Therapeutics
LRMR
$426M
– –
-1,031,482
Closed -$2.02M
LSTA icon
91
Lisata Therapeutics
LSTA
$10.2M
– –
-50,167
Closed -$399K
NTRA icon
92
Natera
NTRA
$39.3B
– –
-1,310,289
Closed -$46.4M
OLMA icon
93
Olema Pharmaceuticals
OLMA
$1.01B
– –
-233,793
Closed -$952K
TERN
94
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,261,435
Closed -$3.13M
VERU icon
95
Veru
VERU
$37.4M
– –
-790,000
Closed -$89.3M
XLO icon
96
Xilio Therapeutics
XLO
$59.9M
– –
-117,837
Closed -$4.82M
TECX
97
Tectonic Therapeutic
TECX
$558M
– –
-46,633
Closed -$515K
LIAN
98
DELISTED
LianBio American Depositary Shares
LIAN
– –
-4,622,574
Closed -$9.98M
ORTX
99
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
– –
-304,089
Closed -$1.78M
PNT
100
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-9,003,018
Closed -$61.3M
1 2 3
4
5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, RA Capital Management held 101 positions worth $4.69B, up 25% from $3.75B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

RA Capital Management deployed $184M of net new capital in Q3 2022, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was Legend Biotech: 2,338,610 shares worth $95.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Concert Pharmaceuticals, Inc., an estimated $13.5M trimmed.

  • RA Capital Management's largest Q3 2022 buy was Legend Biotech: 2,338,610 shares worth $95.4M.
  • RA Capital Management added most to Biogen in Q3 2022, an estimated $44.7M increase.
  • RA Capital Management's biggest Q3 2022 reduction was Concert Pharmaceuticals, Inc., cutting an estimated $13.5M.
  • RA Capital Management fully exited Veru in Q3 2022, selling an estimated $89.3M.
  • RA Capital Management's ten largest holdings make up 46% of its $4.69B portfolio in Q3 2022.
  • RA Capital Management opened 13 new positions and closed 20 in Q3 2022.
  • RA Capital Management's portfolio value rose 25% quarter-over-quarter to $4.69B.

Based on RA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.